Clinical trials: Psoriasis Patients
Plaque Psoriasis
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
The main aim of this study is to assess the effects of switching from another biologic to tildrakizumab on patient-reported outcomes and to assess psoriasis intensity, patient's quality of life prior and after switching and the…
- Trial name
- NCT06030076
- Testing
- Tildrakizumab
- Where
- Austria
- Volunteers
- 50 people
- Sponsor
- Almirall, S.A.
Plaque Psoriasis
A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: Does ESK-001 reduce the severity of people's psoriasis? How safe is ESK-001 in…
- Trial name
- ONWARD2 (NCT06588738)
- Testing
- Envudeucitinib, Apremilast
- Where
- 124 sites in United States, Austria and 10 more
- Volunteers
- 862 people
- Sponsor
- Alumis Inc
Psoriasis Arthritis
GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis
Background Psoriatic arthritis (PsA) patients are at increased risk of cardiovascular disease. Glucagon-Like Peptide-1 (GLP-1) receptor agonists are cardiovascular protective in diabetics.
- Trial name
- NCT07251556
- Testing
- Semaglutide 0.5 mg, Semaglutide 1.0 mg, Semaglutide 0.25 mg
- Volunteers
- 40 people
- Sponsor
- Chinese University of Hong Kong
Psoriasis
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.
- Trial name
- NCT03535194
- Testing
- Mirikizumab, Secukinumab
- Where
- 178 sites in United States, Argentina and 14 more
- Volunteers
- 1,484 people
- Sponsor
- Eli Lilly and Company
Psoriasis
A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate
This purpose of this study is to assess the safety of ustekinumab in psoriasis patients who receive ustekinumab following an inadequate response to methotrexate therapy.
- Trial name
- TRANSIT (NCT01059773)
- Testing
- Ustekinumab, Methotrexate
- Where
- 76 sites in Austria, Belgium and 17 more
- Volunteers
- 490 people
- Sponsor
- Janssen-Cilag International NV
Psoriasis Vulgaris
TAB08 in Patients With Psoriasis Vulgaris, Not Adequately Controlled With Current Treatment
Study to assess Pharmacodynamics, Safety, Pharmacokinetics and clinical effects of TAB08 during 12 weeks of treatment in patients with Psoriasis Vulgaris, not adequately controlled with current therapy.
- Trial name
- NCT02796053
- Testing
- TAB08
- Where
- Russia
- Volunteers
- 9 people
- Sponsor
- Theramab LLC
Psoriasis Vulgaris
Trial in Patients With Psoriasis Treated With Methotrexate Using an Optimized Treatment Schedule (METOP)
This is a multicenter, multinational (12 centers planned, in Germany 9 centers and in France, the Netherlands and the United Kingdom (UK) 1 center in each country respectively), randomized, double-blinded, placebo-controlled…
- Trial name
- METOP (NCT02902861)
- Testing
- Methotrexate
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Prof. Kristian Reich
Inflammatory Arthritis, Cardiovascular Risk Factor
Pharmacist CVD Intervention for Patients With Inflammatory Arthritis
Cardiovascular disease (CVD) (disease of the heart and blood vessels) is one of the leading causes of death and disability in Canada today. The majority of CVD cases are caused by factors that can be controlled.
- Conditions
- Inflammatory Arthritis, Cardiovascular Risk Factor, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- RxIALTA (NCT03152396)
- Testing
- CV risk assessment and modification of global risk
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Epidemiology Coordinating and Research Centre, Canada
Psoriasis Vulgaris
Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris
To gather insight on how product attributes affect usability by investigating the factors that are thought to influence patient preference to topical anti-psoriatic treatments.
- Trial name
- NCT02310646
- Testing
- LEO 90100 Aerosol Foam, Daivobet® gel
- Where
- Canada
- Volunteers
- 219 people
- Sponsor
- LEO Pharma
Psoriatic Arthritis
AsseSSing Impact in pSoriatic Treatment
Psoriatic arthritis (PsA) is a form of inflammatory arthritis associated with the skin condition psoriasis. A variety of different treatments are used to try to control arthritis and skin psoriasis and management often involves…
- Trial name
- ASSIST (NCT05171270)
- Testing
- Questionnaire
- Where
- 21 sites in France, Germany and 3 more
- Volunteers
- 503 people
- Sponsor
- University of Oxford
Psoriasis, Healthy Subjects
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of ABY-035
The purpose of this first-in-human study is to investigate the safety and tolerability of ABY-035 when administered intravenously and subcutaneously, to healthy volunteers and to psoriasis patients.
- Trial name
- NCT02690142
- Testing
- ABY-035 i.v., ABY-035 s.c.
- Where
- 4 sites in United Kingdom
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Affibody
Rheumatoid Arthritis (RA), Atopic Dermatitis (AD)
A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Rheumatoid Arthritis (RA) is an inflammatory disease of the joints characterized by the swelling of multiple joints and tenderness caused by progressive inflammatory synovitis, which leads to serious and debilitating diseases.
- Conditions
- Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA)
- Trial name
- NCT04541810
- Where
- 116 sites in South Korea
- Volunteers
- 2,369 people
- Sponsor
- AbbVie
Chronic Plaque-type Psoriasis
Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis
A randomized, double-blind, placebo and positive controlled, single and multiple dose study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CJM112 in chronic plaque-type psoriasis patients.
- Trial name
- NCT01828086
- Testing
- CJM112, Secukinumab
- Where
- 18 sites in United States
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis (PsO)
A Phase 2 Study of HB0017 in Psoriasis Patients
This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque…
- Trial name
- HB0017 (NCT06592274)
- Testing
- HB0017
- Where
- 18 sites in China
- Volunteers
- 206 people
- Sponsor
- Huabo Biopharm Co., Ltd.
Rheumatoid Arthritis, Ankylosing Spondylitis
Survey of Cannabis Use in Patients With Chronic Inflammatory Arthritis
Patients with inflammatory rheumatism very often have residual pain that is not easily relieved by conventional treatments. They can then use non-drug methods, such as physiotherapy, hypnosis or even cannabis.
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- CannabisRIC (NCT04402554)
- Testing
- Cannabis questionnaire
- Where
- France
- Volunteers
- 501 people
- Sponsor
- University Hospital, Clermont-Ferrand
Chronic Plaque Type Psoriasis
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis
This study assessed efficacy of secukinumab, compared to ustekinumab, in patients that have plaque-type psoriasis
- Trial name
- NCT02074982
- Testing
- AIN457 300 mg, ustekinumab 45/90 mg
- Where
- 137 sites in United States, Australia and 22 more
- Volunteers
- 676 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis
Study GT-030 is a phase 2a, single-center, open-label study of subjects with moderate to severe plaque psoriasis
- Trial name
- NCT02407041
- Testing
- GR-MD-02
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Galectin Therapeutics Inc.
Moderate to Severe Plaque Psoriasis
An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation
This is an open-label study designed to establish the safety and effectiveness of adalimumab in the treatment of moderate to severe plaque psoriasis after 24 weeks of treatment.
- Trial name
- NCT01644396
- Testing
- Adalimumab
- Where
- 7 sites in Russia
- Volunteers
- 50 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Dermatitis, Melanoma (Skin Cancer)
Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care
This study aims to determine if an artificial intelligence (AI) medical device can help doctors more accurately identify a wide variety of skin conditions and improve the efficiency of patient consultations.
- Conditions
- Dermatitis, Melanoma (Skin Cancer), Alopecia, Urticaria
- Trial name
- LegitHealthSAN (NCT07428954)
- Testing
- AI-based medical device for aided diagnosis in Dermatology
- Where
- Spain
- Volunteers
- 16 people
- Sponsor
- AI Labs Group S.L
Moderate to Severe Chronic Plaque-type Psoriasis
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03668613
- Testing
- secukinumab low dose, secukinumab high dose
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.